Sigma Planning Corp Invests $1.09 Million in Eton Pharmaceuticals, Inc. $ETON

Sigma Planning Corp bought a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 30,000 shares of the company’s stock, valued at approximately $1,086,000.

A number of other large investors have also added to or reduced their stakes in ETON. Opaleye Management Inc. lifted its holdings in Eton Pharmaceuticals by 0.3% during the 2nd quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock valued at $40,755,000 after purchasing an additional 7,930 shares during the last quarter. EcoR1 Capital LLC boosted its position in Eton Pharmaceuticals by 7.0% during the first quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after purchasing an additional 141,394 shares during the period. BlackRock Inc. acquired a new position in shares of Eton Pharmaceuticals in the second quarter valued at $68,629,000. Vanguard Group Inc. increased its holdings in shares of Eton Pharmaceuticals by 2.4% in the third quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock valued at $29,208,000 after purchasing an additional 31,942 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new position in shares of Eton Pharmaceuticals in the second quarter valued at about $42,569,426. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Down 0.0%

ETON stock opened at $60.43 on Wednesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of 159.03 and a beta of 0.86. The business’s fifty day moving average price is $46.26 and its two-hundred day moving average price is $32.65. Eton Pharmaceuticals, Inc. has a fifty-two week low of $14.27 and a fifty-two week high of $66.37.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Thursday, August 13th. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.24. The company had revenue of $37.59 million during the quarter, compared to the consensus estimate of $27.11 million. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. On average, equities analysts anticipate that Eton Pharmaceuticals, Inc. will post 1.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ETON. HC Wainwright raised their target price on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. Craig Hallum upped their price target on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Zacks Research raised shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Finally, Canaccord Genuity Group raised their price objective on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $67.50.

Insider Buying and Selling

In other Eton Pharmaceuticals news, insider David Krempa sold 25,000 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $65.07, for a total value of $1,626,750.00. Following the completion of the sale, the insider owned 37,025 shares of the company’s stock, valued at $2,409,216.75. The trade was a 40.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jennifer Mckie Adams sold 50,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the transaction, the director owned 50,000 shares in the company, valued at approximately $1,624,000. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 125,000 shares of company stock valued at $6,204,250. 16.49% of the stock is owned by company insiders.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.